Phuturdex › Diseases › Gastrointestinal neoplasm
Drugs in development · updated 30 October 2026
Gastrointestinal neoplasm: drugs in development
As of 30 October 2026 there are 58 active clinical trials (recruiting or ongoing, phases I–III) on 80 drugs for gastrointestinal neoplasm. 31 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| IDRX-42 | III | 2 | NCT07218926 |
| PF-08634404 | III | 1 | NCT07222800 |
| Velzatinib | II | 5 | NCT07689201 |
| RMC-6236 | I–II | 3 | NCT06445062 |
| AnlotinibAL3818, Anrotinib | II | 2 | NCT05494060 |
| ElironrasibRMC-6291 | I–II | 2 | NCT06128551 |
| RMC-9805 | I–II | 2 | NCT06445062 |
| BAY2927088 | II | 1 | NCT06760819 |
| BenmelstobartTQB2450 | II | 1 | NCT05252078 |
| BHB810 | I–II | 1 | NCT07529808 |
| BNT323 | I–II | 1 | NCT05150691 |
| DB-1303 | I–II | 1 | NCT05150691 |
| DB-1324 | I–II | 1 | NCT07263594 |
| DR30206 | I–II | 1 | NCT07056777 |
| Nuzefatide pevedotinBT5528 | I–II | 1 | NCT04180371 |
| Patritumab deruxtecanU3-1402 | I–II | 1 | NCT06596694 |
| PucotenlimabHX008 | I–II | 1 | NCT03866525 |
| Raludotatug DeruxtecanDS-6000a | II | 1 | NCT06864169 |
| STAR0602 | I–II | 1 | NCT05592626 |
| VS-7375 | I–II | 1 | NCT07020221 |
| 111In-TJD-31 | I | 1 | NCT07815951 |
| DISP-10 | I | 1 | NCT07544589 |
| GRT-C903 | I | 1 | NCT06253520 |
| GRT-R904 | I | 1 | NCT06253520 |
| ISA 51 | I | 1 | NCT06414733 |
| JNJ-89402638 | I | 1 | NCT06663319 |
| LB-100 | I | 1 | NCT06012734 |
| PLT012 | I | 1 | NCT07337525 |
| QXL138AM | I | 1 | NCT06582017 |
| XH001 | I | 1 | NCT07329894 |
| BGT007 | Early I | 1 | NCT06104241 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Bevacizumabavastin, MVASI | III | 5 | NCT07222800 |
| OxaliplatinOxaliplatine, Oxaliplain | II–III | 5 | NCT06028737 |
| CapecitabineXeloda, Capectitabine Tablets | III | 4 | NCT04607421 |
| Fluorouracil5-Fluorouracil, Adrucil | II–III | 4 | NCT06028737 |
| IrinotecanOnivyde, CPT-11 | III | 4 | NCT04607421 |
| CetuximabErbitux | III | 3 | NCT04607421 |
| LeucovorinFolinic acid, l-leucovorin | II–III | 3 | NCT06028737 |
| DocetaxelTaxotere, Beizray® | II–III | 2 | NCT06028737 |
| DabrafenibTafinlar®, Finlee® | II–III | 1 | NCT07440290 |
| DurvalumabMEDI4736, Imfinzi® | III | 1 | NCT04592913 |
| EncorafenibBraftovi® | III | 1 | NCT04607421 |
| EntecavirBaraclude®, Entecavir Viatris (previously Entecavir Mylan)® | III | 1 | NCT06966232 |
| SunitinibSutent®, Sunitinib Accord® | III | 1 | NCT07218926 |
| TrametinibMekinist®, Spexotras® | II–III | 1 | NCT07440290 |
| AldesleukinProleukin | I–II | 2 | NCT03190941 |
Sorted by most advanced phase and number of active trials. Showing 15 of 49 drugs.
All 80 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Colorectal neoplasm 534 drugs
- Stomach neoplasm 340 drugs
- Non-small-cell lung carcinoma 726 drugs
- Esophageal neoplasm 191 drugs
- Esophageal squamous cell carcinoma 115 drugs
- Rectal neoplasm 131 drugs
- Colonic neoplasm 157 drugs
- Pancreatic neoplasm 395 drugs
- Ovarian neoplasm 411 drugs
- Metastasis 493 drugs
- Breast neoplasm 593 drugs
- Neoplasm 671 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Gastrointestinal disease 22 drugs
- Digestive system neoplasm 37 drugs
- Neoplasm 671 drugs
- Colonic disease 11 drugs
- Intestinal disease 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005770 “Gastrointestinal Neoplasms”.